Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.53 |
| ▸ | MTTP | P55157 | 12/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.50 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.50 |
| ▸ | APOB | P04114 | 2/20 | 0.47 |
| ▸ | KLRK1 | P26718 | 3/20 | 0.47 |
| ▸ | MICA | Q29983 | 3/20 | 0.47 |
| ▸ | RAET1L | Q5VY80 | 3/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | RXRG | P48443 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL400773 | 0.91 | PPARA (0.55) | PPARGPPARDPPARANR1H4MTTP | |
| SCHEMBL13580512 | 0.91 | MTTP (0.50) | PPARGPPARDPPARANR1H4MTTP | |
| SCHEMBL402135 | 0.90 | MTTP (0.51) | MTTPAPOBKLRK1MICARAET1L | |
| SCHEMBL402457 | 0.89 | MTTP (0.48) | PPARGPPARDPPARANR1H4MTTP | |
| SCHEMBL13351334 | 0.89 | MEN1 (0.45) | PPARGPPARDPPARANR1H4MTTP | |
| SCHEMBL399742 | 0.89 | MTTP (0.49) | PPARGPPARDPPARANR1H4MTTP | |
| SCHEMBL2597937 | 0.89 | PSEN1 (0.48) | PPARGPPARDPPARANR1H4MTTP | |
| SCHEMBL402136 | 0.87 | MTTP (0.48) | PPARGPPARDPPARANR1H4MTTP | |
| SCHEMBL2597716 | 0.86 | PSEN1 (0.46) | PPARGPPARDPPARANR1H4MTTP | |
| SCHEMBL3723560 | 0.86 | MTTP (0.51) | MTTPKLRK1MICARAET1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571860-A1 | 2-PHENYL BENZOYLAMIDES | Pfizer Inc (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130072519-A1 | 2-PHENYL BENZOYLAMIDES | CONN EDWARD LEE (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120302636-A1 | METHOD OF TREATING A DISORDER ASSOCIATED WITH MTP | AKROS PHARMA INC. | 2012-11-29 | — | — | US | disclosed |
| WO-2011145022-A1 | 2-PHENYL BENZOYLAMIDES | PFIZER INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2010148179-A1 | METHOD OF TREATING A DISORDER ASSOCIATED WITH MTP | JAPAN TOBACCO INC. (JP) | 2010-12-23 | — | — | WO | disclosed |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. | 2010-06-24 | — | — | US | disclosed |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. | 2010-06-24 | — | — | US | disclosed |
| US-7625948-B2 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| US-7625948-B2 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| US-7625948-B2 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2009-12-01 | — | — | US | disclosed |
| US-20050075367-A1 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-04-07 | — | — | US | disclosed |
| EP-1479666-A1 | ESTER COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075367-A1 | Ester compound and medicinal use thereof | LIPC, CES1, MTTP | PPARG 602/4885PPARD 393/4885PPARA 230/4885 |
| US-20120302636-A1 | METHOD OF TREATING A DISORDER ASSOCIATED WITH MTP | MTPN, APOB, HMGCR | PPARG 158/4885PPARD 262/4885PPARA 150/4885 |
| US-20130072519-A1 | 2-PHENYL BENZOYLAMIDES | APOB, MTTP, HADHB | PPARG 570/4885PPARD 516/4885PPARA 351/4885 |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | LIPC, CES1, MTTP | PPARG 458/4885PPARD 359/4885PPARA 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.